Stroke, Vol 15, 306-311, Copyright © 1984 by American Heart Association
T Fukumori, E Tani, Y Maeda and A Sukenaga
Experimental cerebral vasospasm was induced in the canine basilar artery by
an intracisternal injection of fresh autogenous arterial blood. Delayed
vasospasm was defined as a reduction to less than 75% of the caliber of
control basilar artery 5 days after the intracisternal blood injection. A
selective inhibitor of thromboxane A2 synthetase,
sodium(E)-3-[4-(3-pyridylmethyl) phenyl]-2-methyl-2-propenoate, was infused
intravenously for 1 or 2 hrs at 50 micrograms/kg/min in normal animals
exhibiting vasospasm. Angiographic evidence of cerebral vasospasm was not
reversed. Mean regional cerebral blood flow was not significantly increased
in normal and vasospastic animals, but a mean difference of regional
cerebral blood flow was significantly increased only in vasospastic
animals. Mean arterial blood pressure and pulse rate were not seriously
changed in normal and spastic animals. Another selective thromboxane A2
synthetase inhibitor, (E)-3-[4-(1- imidazolylmethyl)phenyl]-2-propenoic
acid hydrochloride monohydrate, showed a similar effect on the caliber of
the basilar artery, regional cerebral blood flow, blood pressure, and pulse
rate, in vasospastic animals. Venous blood was taken from the internal
jugular vein, and the mean platelet aggregation induced by 10 micrograms/ml
of collagen was inhibited by the infusion of either selective inhibitor at
50 micrograms/kg/min for 2 hrs. However, mean platelet aggregation rates in
vasospastic animals before and after treatment with either selective
inhibitor were not significantly different to those in normal animals.
ARTICLES
Effect of selective inhibitor of thromboxane A2 synthetase on experimental cerebral vasospasm
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1984 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |